| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 184 | 2024 | 861 | 26.650 |
Why?
|
| Kidney Failure, Chronic | 167 | 2024 | 887 | 25.830 |
Why?
|
| Renal Insufficiency, Chronic | 93 | 2025 | 736 | 12.970 |
Why?
|
| Kidney Transplantation | 72 | 2024 | 653 | 10.680 |
Why?
|
| Kidney Diseases | 51 | 2024 | 483 | 8.010 |
Why?
|
| Anemia | 37 | 2023 | 341 | 7.530 |
Why?
|
| Atrial Fibrillation | 32 | 2024 | 657 | 6.680 |
Why?
|
| Hematinics | 31 | 2023 | 60 | 6.620 |
Why?
|
| Nephrology | 39 | 2023 | 148 | 6.340 |
Why?
|
| Peritoneal Dialysis | 21 | 2023 | 127 | 5.750 |
Why?
|
| Medicare | 44 | 2023 | 427 | 4.710 |
Why?
|
| Anticoagulants | 22 | 2024 | 576 | 4.520 |
Why?
|
| Glomerular Filtration Rate | 44 | 2025 | 510 | 4.430 |
Why?
|
| Kidney | 44 | 2023 | 1360 | 4.300 |
Why?
|
| Erythropoietin | 21 | 2023 | 106 | 4.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 22 | 2021 | 217 | 3.920 |
Why?
|
| Aged | 198 | 2025 | 19656 | 3.830 |
Why?
|
| Myocardial Infarction | 28 | 2023 | 1042 | 3.790 |
Why?
|
| United States | 141 | 2025 | 10884 | 3.670 |
Why?
|
| Hip Fractures | 8 | 2020 | 67 | 3.650 |
Why?
|
| Warfarin | 11 | 2022 | 118 | 3.330 |
Why?
|
| Humans | 441 | 2025 | 125110 | 3.270 |
Why?
|
| Acute Kidney Injury | 21 | 2022 | 649 | 3.190 |
Why?
|
| Middle Aged | 184 | 2025 | 26676 | 3.020 |
Why?
|
| Male | 264 | 2025 | 61443 | 3.020 |
Why?
|
| Female | 273 | 2025 | 66704 | 2.930 |
Why?
|
| Renal Replacement Therapy | 11 | 2021 | 146 | 2.830 |
Why?
|
| Stroke | 22 | 2022 | 982 | 2.780 |
Why?
|
| Risk Assessment | 41 | 2024 | 3424 | 2.670 |
Why?
|
| Cardiovascular Diseases | 36 | 2022 | 1958 | 2.650 |
Why?
|
| Glomerulonephritis | 6 | 2019 | 74 | 2.640 |
Why?
|
| Hemorrhage | 13 | 2024 | 469 | 2.440 |
Why?
|
| Terminology as Topic | 10 | 2020 | 224 | 2.430 |
Why?
|
| Aged, 80 and over | 75 | 2024 | 6537 | 2.390 |
Why?
|
| Angiotensin Receptor Antagonists | 9 | 2021 | 128 | 2.360 |
Why?
|
| Risk Factors | 87 | 2023 | 10278 | 2.290 |
Why?
|
| Renal Insufficiency | 9 | 2024 | 238 | 2.250 |
Why?
|
| Medicaid | 19 | 2019 | 242 | 2.170 |
Why?
|
| Hypertension | 17 | 2024 | 1286 | 2.150 |
Why?
|
| Incidence | 42 | 2022 | 3131 | 2.130 |
Why?
|
| Cohort Studies | 65 | 2022 | 4821 | 2.110 |
Why?
|
| Iron | 14 | 2023 | 276 | 1.940 |
Why?
|
| Diabetic Nephropathies | 9 | 2019 | 110 | 1.890 |
Why?
|
| Cause of Death | 20 | 2019 | 474 | 1.890 |
Why?
|
| Proportional Hazards Models | 34 | 2021 | 1361 | 1.890 |
Why?
|
| Practice Patterns, Physicians' | 15 | 2021 | 729 | 1.890 |
Why?
|
| Hypoglycemic Agents | 10 | 2022 | 443 | 1.810 |
Why?
|
| Cardiovascular Agents | 7 | 2012 | 89 | 1.800 |
Why?
|
| Prognosis | 39 | 2023 | 4683 | 1.750 |
Why?
|
| Retrospective Studies | 87 | 2024 | 16338 | 1.730 |
Why?
|
| Time Factors | 57 | 2024 | 6301 | 1.680 |
Why?
|
| Adult | 101 | 2024 | 29460 | 1.610 |
Why?
|
| Treatment Outcome | 70 | 2024 | 12272 | 1.600 |
Why?
|
| Blood Pressure | 10 | 2023 | 1351 | 1.530 |
Why?
|
| Ferric Compounds | 5 | 2023 | 38 | 1.520 |
Why?
|
| Delivery of Health Care | 5 | 2020 | 615 | 1.500 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 10 | 2010 | 55 | 1.490 |
Why?
|
| Coronary Artery Bypass | 9 | 2016 | 516 | 1.450 |
Why?
|
| Antihypertensive Agents | 12 | 2021 | 389 | 1.450 |
Why?
|
| Diabetes Mellitus | 13 | 2020 | 873 | 1.440 |
Why?
|
| Hospitalization | 25 | 2021 | 1784 | 1.440 |
Why?
|
| Graft Survival | 17 | 2019 | 532 | 1.440 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2022 | 1273 | 1.430 |
Why?
|
| Mortality | 8 | 2018 | 238 | 1.390 |
Why?
|
| Prospective Payment System | 6 | 2021 | 16 | 1.380 |
Why?
|
| Fibrinolytic Agents | 3 | 2024 | 192 | 1.360 |
Why?
|
| Follow-Up Studies | 41 | 2022 | 5169 | 1.350 |
Why?
|
| Caregivers | 7 | 2022 | 540 | 1.350 |
Why?
|
| Heparin | 6 | 2014 | 217 | 1.350 |
Why?
|
| Referral and Consultation | 9 | 2012 | 543 | 1.340 |
Why?
|
| Glycine | 7 | 2022 | 168 | 1.340 |
Why?
|
| Altitude | 4 | 2012 | 22 | 1.340 |
Why?
|
| Arteriovenous Shunt, Surgical | 7 | 2024 | 91 | 1.330 |
Why?
|
| Heart Failure | 15 | 2021 | 2297 | 1.290 |
Why?
|
| Homocysteine | 7 | 2005 | 115 | 1.260 |
Why?
|
| Coronary Disease | 7 | 2016 | 671 | 1.260 |
Why?
|
| Survival Rate | 27 | 2022 | 2051 | 1.250 |
Why?
|
| Registries | 19 | 2025 | 1434 | 1.240 |
Why?
|
| Percutaneous Coronary Intervention | 6 | 2017 | 254 | 1.230 |
Why?
|
| Renin-Angiotensin System | 5 | 2021 | 100 | 1.210 |
Why?
|
| Glucaric Acid | 4 | 2023 | 10 | 1.210 |
Why?
|
| Population Surveillance | 4 | 2022 | 390 | 1.200 |
Why?
|
| Hyperkalemia | 6 | 2024 | 67 | 1.170 |
Why?
|
| Comorbidity | 21 | 2020 | 1526 | 1.160 |
Why?
|
| Graft Rejection | 12 | 2024 | 588 | 1.160 |
Why?
|
| Potassium | 7 | 2024 | 284 | 1.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2020 | 730 | 1.150 |
Why?
|
| Hemoglobins | 17 | 2023 | 312 | 1.110 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2014 | 231 | 1.070 |
Why?
|
| Economic Competition | 4 | 2023 | 14 | 1.070 |
Why?
|
| Living Donors | 3 | 2024 | 113 | 1.060 |
Why?
|
| Darbepoetin alfa | 10 | 2023 | 14 | 1.060 |
Why?
|
| Practice Guidelines as Topic | 12 | 2021 | 1265 | 1.050 |
Why?
|
| Thrombosis | 3 | 2024 | 520 | 1.050 |
Why?
|
| Medication Adherence | 4 | 2012 | 397 | 1.050 |
Why?
|
| Coronary Artery Disease | 8 | 2019 | 805 | 1.020 |
Why?
|
| Health Policy | 5 | 2021 | 214 | 0.990 |
Why?
|
| Proton Pump Inhibitors | 3 | 2022 | 278 | 0.950 |
Why?
|
| Factor XI | 2 | 2024 | 3 | 0.940 |
Why?
|
| Drug Prescriptions | 10 | 2024 | 220 | 0.940 |
Why?
|
| Anemia, Iron-Deficiency | 6 | 2023 | 138 | 0.930 |
Why?
|
| Glomerulonephritis, IGA | 3 | 2019 | 16 | 0.910 |
Why?
|
| Hyperphosphatemia | 4 | 2016 | 17 | 0.900 |
Why?
|
| Disease Progression | 15 | 2025 | 2084 | 0.900 |
Why?
|
| Patient Outcome Assessment | 4 | 2020 | 92 | 0.900 |
Why?
|
| Altruism | 1 | 2024 | 24 | 0.900 |
Why?
|
| Kidney Function Tests | 10 | 2022 | 130 | 0.890 |
Why?
|
| National Health Programs | 2 | 2023 | 19 | 0.890 |
Why?
|
| Multivariate Analysis | 21 | 2016 | 1425 | 0.880 |
Why?
|
| Adrenergic beta-Antagonists | 9 | 2018 | 238 | 0.860 |
Why?
|
| Death, Sudden, Cardiac | 8 | 2022 | 259 | 0.850 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2024 | 1685 | 0.840 |
Why?
|
| Health Services Accessibility | 9 | 2021 | 605 | 0.840 |
Why?
|
| Aftercare | 1 | 2024 | 146 | 0.820 |
Why?
|
| Folic Acid | 6 | 2005 | 293 | 0.820 |
Why?
|
| Nephrectomy | 1 | 2024 | 176 | 0.820 |
Why?
|
| Insurance, Health | 4 | 2018 | 139 | 0.820 |
Why?
|
| Young Adult | 33 | 2020 | 9056 | 0.820 |
Why?
|
| Electronic Health Records | 6 | 2017 | 721 | 0.790 |
Why?
|
| Patients | 2 | 2020 | 119 | 0.790 |
Why?
|
| Health Care Costs | 8 | 2020 | 371 | 0.790 |
Why?
|
| Picolinic Acids | 5 | 2022 | 10 | 0.780 |
Why?
|
| Prolyl-Hydroxylase Inhibitors | 4 | 2023 | 4 | 0.760 |
Why?
|
| Ficus | 1 | 2021 | 2 | 0.740 |
Why?
|
| Coffee | 2 | 2015 | 26 | 0.740 |
Why?
|
| Hypolipidemic Agents | 6 | 2020 | 183 | 0.740 |
Why?
|
| Logistic Models | 16 | 2020 | 1800 | 0.740 |
Why?
|
| Survival Analysis | 15 | 2018 | 1496 | 0.740 |
Why?
|
| Postoperative Complications | 9 | 2020 | 3047 | 0.730 |
Why?
|
| Ambulatory Care | 7 | 2021 | 390 | 0.730 |
Why?
|
| Immunosuppressive Agents | 11 | 2019 | 645 | 0.730 |
Why?
|
| Diabetes Complications | 2 | 2015 | 201 | 0.720 |
Why?
|
| Vitamin B 12 | 4 | 2005 | 59 | 0.720 |
Why?
|
| Caffeine | 2 | 2015 | 71 | 0.720 |
Why?
|
| Stents | 3 | 2017 | 835 | 0.720 |
Why?
|
| Central Venous Catheters | 2 | 2018 | 38 | 0.710 |
Why?
|
| Decision Making | 5 | 2020 | 656 | 0.710 |
Why?
|
| Patient Discharge | 4 | 2014 | 492 | 0.710 |
Why?
|
| Drug Utilization | 7 | 2020 | 157 | 0.710 |
Why?
|
| Depression | 3 | 2019 | 1233 | 0.710 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 361 | 0.700 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 377 | 0.700 |
Why?
|
| Betacoronavirus | 3 | 2020 | 290 | 0.700 |
Why?
|
| Lupus Nephritis | 7 | 2015 | 42 | 0.700 |
Why?
|
| Cross-Sectional Studies | 17 | 2024 | 3402 | 0.690 |
Why?
|
| Isoquinolines | 2 | 2021 | 40 | 0.680 |
Why?
|
| Carbonated Beverages | 2 | 2012 | 11 | 0.650 |
Why?
|
| Drug Utilization Review | 4 | 2007 | 33 | 0.650 |
Why?
|
| Research Design | 9 | 2018 | 693 | 0.650 |
Why?
|
| Thiazolidinediones | 3 | 2010 | 82 | 0.650 |
Why?
|
| Comparative Effectiveness Research | 4 | 2017 | 68 | 0.640 |
Why?
|
| Databases, Factual | 13 | 2020 | 1172 | 0.640 |
Why?
|
| Clinical Trials as Topic | 8 | 2020 | 1095 | 0.640 |
Why?
|
| Reimbursement Mechanisms | 5 | 2023 | 36 | 0.640 |
Why?
|
| Tacrolimus | 6 | 2019 | 97 | 0.630 |
Why?
|
| Dialysis | 1 | 2019 | 21 | 0.630 |
Why?
|
| Pandemics | 4 | 2021 | 1112 | 0.630 |
Why?
|
| Global Health | 3 | 2020 | 570 | 0.620 |
Why?
|
| Secondary Prevention | 5 | 2012 | 215 | 0.620 |
Why?
|
| Algorithms | 8 | 2019 | 1630 | 0.610 |
Why?
|
| Prevalence | 17 | 2022 | 2458 | 0.610 |
Why?
|
| Guideline Adherence | 4 | 2018 | 370 | 0.610 |
Why?
|
| Pyridines | 3 | 2018 | 235 | 0.610 |
Why?
|
| AIDS-Associated Nephropathy | 2 | 2018 | 76 | 0.600 |
Why?
|
| Metoprolol | 1 | 2018 | 22 | 0.600 |
Why?
|
| Analgesics, Opioid | 2 | 2020 | 409 | 0.600 |
Why?
|
| Histamine H2 Antagonists | 1 | 2018 | 50 | 0.590 |
Why?
|
| Medicare Part D | 2 | 2016 | 17 | 0.590 |
Why?
|
| Adolescent | 34 | 2022 | 19414 | 0.590 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2022 | 1114 | 0.590 |
Why?
|
| Age Factors | 15 | 2018 | 2815 | 0.580 |
Why?
|
| Evidence-Based Medicine | 6 | 2020 | 627 | 0.580 |
Why?
|
| Creatinine | 8 | 2022 | 393 | 0.580 |
Why?
|
| Employment | 2 | 2018 | 64 | 0.580 |
Why?
|
| Intracranial Hemorrhages | 4 | 2014 | 76 | 0.580 |
Why?
|
| Intensive Care Units | 1 | 2021 | 493 | 0.580 |
Why?
|
| Ferrosoferric Oxide | 2 | 2015 | 27 | 0.570 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2016 | 2654 | 0.570 |
Why?
|
| Attitude to Health | 3 | 2019 | 255 | 0.570 |
Why?
|
| Brain Ischemia | 4 | 2019 | 265 | 0.570 |
Why?
|
| Ambulatory Care Facilities | 7 | 2021 | 225 | 0.570 |
Why?
|
| Albuminuria | 5 | 2020 | 103 | 0.570 |
Why?
|
| Healthcare Disparities | 7 | 2024 | 439 | 0.560 |
Why?
|
| Patient Compliance | 4 | 2008 | 470 | 0.560 |
Why?
|
| Hyperparathyroidism | 2 | 2010 | 25 | 0.560 |
Why?
|
| United States Food and Drug Administration | 4 | 2013 | 150 | 0.540 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 4 | 2006 | 70 | 0.540 |
Why?
|
| Congresses as Topic | 8 | 2024 | 174 | 0.530 |
Why?
|
| Quality of Life | 12 | 2023 | 1906 | 0.530 |
Why?
|
| Erythropoiesis | 4 | 2022 | 42 | 0.530 |
Why?
|
| Air Pollution | 2 | 2021 | 66 | 0.520 |
Why?
|
| Program Evaluation | 3 | 2018 | 440 | 0.520 |
Why?
|
| Epoetin Alfa | 6 | 2016 | 9 | 0.520 |
Why?
|
| Nephrologists | 4 | 2021 | 13 | 0.520 |
Why?
|
| Consensus | 13 | 2023 | 645 | 0.510 |
Why?
|
| Hyperhomocysteinemia | 4 | 2006 | 37 | 0.510 |
Why?
|
| Chelating Agents | 4 | 2016 | 42 | 0.510 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2014 | 1123 | 0.500 |
Why?
|
| Models, Biological | 1 | 2021 | 1465 | 0.500 |
Why?
|
| Barbiturates | 1 | 2015 | 7 | 0.500 |
Why?
|
| Acetates | 3 | 2011 | 73 | 0.500 |
Why?
|
| Confidence Intervals | 9 | 2016 | 283 | 0.500 |
Why?
|
| Air Pollutants | 2 | 2021 | 102 | 0.500 |
Why?
|
| Blood Glucose | 2 | 2017 | 1133 | 0.500 |
Why?
|
| Delayed Graft Function | 2 | 2013 | 3 | 0.490 |
Why?
|
| Lupus Erythematosus, Systemic | 5 | 2017 | 193 | 0.490 |
Why?
|
| Health Status | 5 | 2017 | 375 | 0.490 |
Why?
|
| Reimbursement, Incentive | 2 | 2018 | 48 | 0.490 |
Why?
|
| Administration, Oral | 6 | 2021 | 683 | 0.490 |
Why?
|
| Women's Health | 6 | 2021 | 134 | 0.490 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 260 | 0.490 |
Why?
|
| Vascular Diseases | 2 | 2018 | 155 | 0.480 |
Why?
|
| Ferredoxin-NADP Reductase | 2 | 2005 | 10 | 0.480 |
Why?
|
| Terminal Care | 2 | 2014 | 112 | 0.480 |
Why?
|
| Bone Density Conservation Agents | 2 | 2017 | 52 | 0.470 |
Why?
|
| Austria | 10 | 2020 | 19 | 0.470 |
Why?
|
| Fenoldopam | 1 | 2014 | 9 | 0.470 |
Why?
|
| Patient Care Bundles | 2 | 2021 | 22 | 0.470 |
Why?
|
| Publishing | 3 | 2020 | 109 | 0.470 |
Why?
|
| Focus Groups | 6 | 2022 | 190 | 0.470 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2016 | 75 | 0.460 |
Why?
|
| Time-to-Treatment | 2 | 2019 | 186 | 0.460 |
Why?
|
| Metformin | 2 | 2021 | 150 | 0.460 |
Why?
|
| Clonidine | 1 | 2014 | 36 | 0.460 |
Why?
|
| Dialysis Solutions | 4 | 2024 | 12 | 0.460 |
Why?
|
| Polymers | 1 | 2015 | 104 | 0.460 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2014 | 26 | 0.460 |
Why?
|
| Chronic Disease | 11 | 2011 | 1187 | 0.450 |
Why?
|
| Hemodialysis Units, Hospital | 4 | 2020 | 9 | 0.450 |
Why?
|
| Depressive Disorder | 1 | 2017 | 454 | 0.440 |
Why?
|
| Off-Label Use | 2 | 2012 | 28 | 0.440 |
Why?
|
| Phosphates | 3 | 2016 | 115 | 0.440 |
Why?
|
| Plasma Substitutes | 2 | 2003 | 7 | 0.430 |
Why?
|
| Hydroxyethyl Starch Derivatives | 2 | 2003 | 8 | 0.430 |
Why?
|
| Coronary Stenosis | 1 | 2014 | 77 | 0.430 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2014 | 55 | 0.430 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 260 | 0.430 |
Why?
|
| Residence Characteristics | 4 | 2013 | 270 | 0.430 |
Why?
|
| Hypotension | 3 | 2020 | 186 | 0.420 |
Why?
|
| Cyclosporine | 4 | 2019 | 145 | 0.420 |
Why?
|
| Rhabdomyolysis | 1 | 2013 | 37 | 0.420 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2014 | 180 | 0.420 |
Why?
|
| Prospective Studies | 20 | 2025 | 6123 | 0.420 |
Why?
|
| C-Reactive Protein | 3 | 2007 | 434 | 0.420 |
Why?
|
| Vasodilator Agents | 1 | 2014 | 202 | 0.420 |
Why?
|
| Pregnancy Complications | 2 | 2015 | 515 | 0.420 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2013 | 23 | 0.410 |
Why?
|
| Thromboembolism | 3 | 2021 | 89 | 0.410 |
Why?
|
| Aspirin | 1 | 2014 | 222 | 0.410 |
Why?
|
| Mycophenolic Acid | 3 | 2017 | 49 | 0.410 |
Why?
|
| Insurance Claim Reporting | 2 | 2012 | 8 | 0.410 |
Why?
|
| Counseling | 1 | 2014 | 220 | 0.410 |
Why?
|
| Case-Control Studies | 9 | 2022 | 3310 | 0.410 |
Why?
|
| Qualitative Research | 5 | 2018 | 535 | 0.400 |
Why?
|
| Drinking Behavior | 1 | 2012 | 9 | 0.400 |
Why?
|
| Polyamines | 3 | 2012 | 27 | 0.400 |
Why?
|
| Particulate Matter | 2 | 2021 | 70 | 0.400 |
Why?
|
| New Jersey | 8 | 2012 | 23 | 0.400 |
Why?
|
| Critical Illness | 2 | 2020 | 599 | 0.400 |
Why?
|
| Postoperative Hemorrhage | 2 | 2003 | 83 | 0.400 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 265 | 0.390 |
Why?
|
| Chlorides | 1 | 2012 | 107 | 0.390 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 668 | 0.390 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2012 | 9 | 0.380 |
Why?
|
| Blood Transfusion | 1 | 2014 | 312 | 0.380 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2017 | 304 | 0.380 |
Why?
|
| Socioeconomic Factors | 7 | 2019 | 858 | 0.380 |
Why?
|
| Fluid Therapy | 1 | 2012 | 129 | 0.380 |
Why?
|
| Pennsylvania | 5 | 2012 | 54 | 0.370 |
Why?
|
| Venous Thromboembolism | 1 | 2014 | 165 | 0.370 |
Why?
|
| Intestinal Perforation | 1 | 2012 | 56 | 0.370 |
Why?
|
| Naphthalenes | 2 | 2012 | 37 | 0.370 |
Why?
|
| Longitudinal Studies | 7 | 2020 | 1320 | 0.370 |
Why?
|
| Biomedical Research | 6 | 2018 | 516 | 0.370 |
Why?
|
| Ozone | 1 | 2011 | 18 | 0.370 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2015 | 664 | 0.370 |
Why?
|
| Communication | 3 | 2020 | 507 | 0.360 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2011 | 54 | 0.360 |
Why?
|
| Vitamin D | 2 | 2010 | 166 | 0.360 |
Why?
|
| Tissue and Organ Procurement | 4 | 2021 | 222 | 0.360 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2017 | 1066 | 0.350 |
Why?
|
| Health Facility Closure | 2 | 2021 | 8 | 0.350 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 2010 | 13 | 0.350 |
Why?
|
| Calcium Carbonate | 1 | 2010 | 10 | 0.350 |
Why?
|
| Postmenopause | 3 | 2015 | 126 | 0.350 |
Why?
|
| Prescription Drugs | 2 | 2012 | 54 | 0.350 |
Why?
|
| Obesity | 2 | 2020 | 2244 | 0.340 |
Why?
|
| Textiles | 2 | 2020 | 10 | 0.340 |
Why?
|
| Odds Ratio | 8 | 2021 | 1253 | 0.340 |
Why?
|
| Body Mass Index | 5 | 2020 | 1563 | 0.340 |
Why?
|
| Sex Distribution | 6 | 2018 | 305 | 0.340 |
Why?
|
| Heart-Assist Devices | 4 | 2020 | 1026 | 0.340 |
Why?
|
| Defibrillators, Implantable | 2 | 2018 | 190 | 0.340 |
Why?
|
| Masks | 2 | 2020 | 38 | 0.330 |
Why?
|
| Double-Blind Method | 6 | 2024 | 1605 | 0.330 |
Why?
|
| Feeding Behavior | 1 | 2015 | 695 | 0.330 |
Why?
|
| Catheterization, Central Venous | 2 | 2011 | 128 | 0.330 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2011 | 115 | 0.330 |
Why?
|
| Transplant Recipients | 5 | 2024 | 218 | 0.330 |
Why?
|
| Health Services for the Aged | 1 | 2010 | 38 | 0.330 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2010 | 34 | 0.330 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2020 | 847 | 0.320 |
Why?
|
| Endpoint Determination | 4 | 2018 | 57 | 0.320 |
Why?
|
| Recombinant Proteins | 7 | 2015 | 1400 | 0.320 |
Why?
|
| Sevelamer | 4 | 2016 | 11 | 0.320 |
Why?
|
| Drug Hypersensitivity | 1 | 2010 | 96 | 0.320 |
Why?
|
| Anaphylaxis | 1 | 2010 | 82 | 0.320 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2008 | 57 | 0.300 |
Why?
|
| Blood Coagulation | 2 | 2024 | 123 | 0.300 |
Why?
|
| Administration, Intravenous | 4 | 2017 | 143 | 0.300 |
Why?
|
| Severity of Illness Index | 9 | 2025 | 2906 | 0.300 |
Why?
|
| Models, Statistical | 9 | 2015 | 469 | 0.290 |
Why?
|
| Venous Thrombosis | 2 | 2013 | 167 | 0.290 |
Why?
|
| Phosphorus | 2 | 2011 | 58 | 0.290 |
Why?
|
| Cost-Benefit Analysis | 7 | 2013 | 511 | 0.290 |
Why?
|
| International Classification of Diseases | 2 | 2006 | 92 | 0.290 |
Why?
|
| Drugs, Generic | 2 | 2020 | 13 | 0.290 |
Why?
|
| Drug Administration Schedule | 6 | 2014 | 728 | 0.290 |
Why?
|
| Pulmonary Embolism | 2 | 2013 | 174 | 0.280 |
Why?
|
| Health Care Sector | 2 | 2018 | 19 | 0.280 |
Why?
|
| Myocardial Revascularization | 1 | 2008 | 103 | 0.280 |
Why?
|
| Hyperlipidemias | 3 | 2020 | 177 | 0.280 |
Why?
|
| Hemodialysis, Home | 4 | 2023 | 12 | 0.280 |
Why?
|
| Patient Participation | 3 | 2020 | 218 | 0.280 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2015 | 763 | 0.280 |
Why?
|
| Predictive Value of Tests | 7 | 2021 | 2182 | 0.280 |
Why?
|
| Hospital Mortality | 5 | 2019 | 1027 | 0.270 |
Why?
|
| Length of Stay | 4 | 2008 | 1306 | 0.270 |
Why?
|
| Benzodiazepines | 1 | 2007 | 102 | 0.270 |
Why?
|
| Peripheral Arterial Disease | 2 | 2021 | 289 | 0.270 |
Why?
|
| Anti-Anxiety Agents | 1 | 2007 | 74 | 0.270 |
Why?
|
| Patient Readmission | 4 | 2020 | 382 | 0.270 |
Why?
|
| Hemodialysis Solutions | 3 | 2024 | 6 | 0.270 |
Why?
|
| Propensity Score | 7 | 2021 | 221 | 0.260 |
Why?
|
| Losartan | 1 | 2006 | 34 | 0.260 |
Why?
|
| Fee-for-Service Plans | 2 | 2016 | 18 | 0.260 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 471 | 0.260 |
Why?
|
| Diagnosis-Related Groups | 2 | 2006 | 27 | 0.260 |
Why?
|
| Causality | 2 | 2017 | 84 | 0.260 |
Why?
|
| Intraoperative Care | 2 | 2003 | 105 | 0.260 |
Why?
|
| Hematocrit | 4 | 2011 | 114 | 0.260 |
Why?
|
| Calcium | 3 | 2011 | 1105 | 0.250 |
Why?
|
| Patient Care Planning | 3 | 2019 | 121 | 0.250 |
Why?
|
| Drug-Eluting Stents | 2 | 2017 | 63 | 0.250 |
Why?
|
| Patient Preference | 5 | 2019 | 118 | 0.250 |
Why?
|
| Quality-Adjusted Life Years | 5 | 2011 | 112 | 0.250 |
Why?
|
| Waiting Lists | 4 | 2024 | 227 | 0.250 |
Why?
|
| Biomarkers | 9 | 2024 | 3105 | 0.250 |
Why?
|
| Outpatients | 2 | 2019 | 250 | 0.240 |
Why?
|
| Citalopram | 2 | 2022 | 30 | 0.240 |
Why?
|
| Health Expenditures | 3 | 2022 | 103 | 0.240 |
Why?
|
| Consensus Development Conferences as Topic | 6 | 2020 | 39 | 0.240 |
Why?
|
| Catheters, Indwelling | 1 | 2006 | 138 | 0.240 |
Why?
|
| Sertraline | 2 | 2022 | 44 | 0.240 |
Why?
|
| Anemia, Hypochromic | 1 | 2004 | 7 | 0.240 |
Why?
|
| Regression Analysis | 5 | 2015 | 776 | 0.230 |
Why?
|
| Risk | 5 | 2013 | 759 | 0.230 |
Why?
|
| Silicates | 1 | 2024 | 10 | 0.230 |
Why?
|
| 5,10-Methylenetetrahydrofolate Reductase (FADH2) | 1 | 2004 | 4 | 0.230 |
Why?
|
| Erythrocytes | 2 | 2005 | 221 | 0.230 |
Why?
|
| Health Resources | 2 | 2017 | 116 | 0.230 |
Why?
|
| Statistics as Topic | 2 | 2015 | 256 | 0.230 |
Why?
|
| Data Mining | 2 | 2016 | 51 | 0.230 |
Why?
|
| Torsades de Pointes | 2 | 2024 | 6 | 0.230 |
Why?
|
| Forearm | 1 | 2024 | 45 | 0.230 |
Why?
|
| Fluoroquinolones | 2 | 2022 | 86 | 0.230 |
Why?
|
| Coronary Angiography | 1 | 2007 | 449 | 0.230 |
Why?
|
| Transcobalamins | 1 | 2004 | 4 | 0.230 |
Why?
|
| Vascular Access Devices | 2 | 2014 | 33 | 0.230 |
Why?
|
| Artificial Intelligence | 3 | 2023 | 245 | 0.230 |
Why?
|
| Chi-Square Distribution | 6 | 2013 | 584 | 0.230 |
Why?
|
| Therapeutics | 1 | 2004 | 7 | 0.220 |
Why?
|
| Blood Pressure Determination | 3 | 2020 | 111 | 0.220 |
Why?
|
| Health Surveys | 2 | 2021 | 243 | 0.220 |
Why?
|
| Complement Activation | 1 | 2024 | 52 | 0.220 |
Why?
|
| Surveys and Questionnaires | 6 | 2020 | 3675 | 0.220 |
Why?
|
| Morbidity | 3 | 2020 | 248 | 0.220 |
Why?
|
| Vocabulary, Controlled | 2 | 2020 | 12 | 0.220 |
Why?
|
| Delphi Technique | 4 | 2020 | 210 | 0.220 |
Why?
|
| Transplantation, Homologous | 6 | 2023 | 621 | 0.220 |
Why?
|
| Oligonucleotides | 1 | 2024 | 91 | 0.220 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2003 | 6 | 0.210 |
Why?
|
| Analysis of Variance | 5 | 2012 | 1017 | 0.210 |
Why?
|
| Cross-Over Studies | 1 | 2024 | 317 | 0.210 |
Why?
|
| Physicians | 2 | 2014 | 581 | 0.210 |
Why?
|
| Comprehension | 2 | 2020 | 74 | 0.210 |
Why?
|
| Antigens, Surface | 1 | 2003 | 118 | 0.200 |
Why?
|
| Germany | 1 | 2022 | 66 | 0.200 |
Why?
|
| Time | 2 | 2016 | 91 | 0.200 |
Why?
|
| Genotype | 6 | 2019 | 2569 | 0.200 |
Why?
|
| Embolism | 1 | 2022 | 46 | 0.200 |
Why?
|
| Hypokalemia | 2 | 2019 | 41 | 0.200 |
Why?
|
| Nephrosis, Lipoid | 2 | 2019 | 11 | 0.190 |
Why?
|
| Diuretics | 2 | 2021 | 167 | 0.190 |
Why?
|
| Hypertension, Pulmonary | 2 | 2021 | 439 | 0.190 |
Why?
|
| Health Facility Merger | 2 | 2019 | 8 | 0.190 |
Why?
|
| Azithromycin | 1 | 2022 | 43 | 0.190 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 174 | 0.190 |
Why?
|
| Ferritins | 5 | 2023 | 100 | 0.190 |
Why?
|
| Nutrition Surveys | 2 | 2021 | 295 | 0.190 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2022 | 24 | 0.190 |
Why?
|
| Preventive Health Services | 1 | 2002 | 60 | 0.190 |
Why?
|
| Patient Safety | 4 | 2015 | 397 | 0.190 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2025 | 261 | 0.180 |
Why?
|
| Calcium Compounds | 3 | 2011 | 7 | 0.180 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2002 | 116 | 0.180 |
Why?
|
| Prosthesis Implantation | 2 | 2020 | 140 | 0.180 |
Why?
|
| Respiratory Tract Diseases | 1 | 2022 | 75 | 0.180 |
Why?
|
| Annual Reports as Topic | 1 | 2021 | 2 | 0.180 |
Why?
|
| Symporters | 1 | 2022 | 70 | 0.180 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2021 | 8 | 0.180 |
Why?
|
| Age Distribution | 3 | 2015 | 418 | 0.180 |
Why?
|
| Mathematical Concepts | 1 | 2021 | 7 | 0.180 |
Why?
|
| Genetic Testing | 2 | 2019 | 1016 | 0.180 |
Why?
|
| Cost of Illness | 3 | 2019 | 251 | 0.180 |
Why?
|
| Uremia | 1 | 2001 | 36 | 0.180 |
Why?
|
| Polymorphism, Genetic | 2 | 2006 | 819 | 0.180 |
Why?
|
| Australia | 5 | 2020 | 139 | 0.180 |
Why?
|
| Poverty | 2 | 2014 | 420 | 0.180 |
Why?
|
| Transferrin | 4 | 2013 | 49 | 0.180 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2021 | 63 | 0.170 |
Why?
|
| Hospitals, Veterans | 2 | 2021 | 350 | 0.170 |
Why?
|
| Neoplasms | 5 | 2020 | 2794 | 0.170 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2024 | 457 | 0.170 |
Why?
|
| Frustration | 1 | 2020 | 8 | 0.170 |
Why?
|
| Drug Costs | 4 | 2015 | 61 | 0.170 |
Why?
|
| Inpatients | 2 | 2019 | 497 | 0.170 |
Why?
|
| Saphenous Vein | 2 | 2013 | 59 | 0.170 |
Why?
|
| Vitamin K | 1 | 2020 | 37 | 0.170 |
Why?
|
| Minority Groups | 2 | 2013 | 243 | 0.170 |
Why?
|
| Polypharmacy | 1 | 2020 | 40 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 509 | 0.160 |
Why?
|
| Monitoring, Physiologic | 2 | 2012 | 377 | 0.160 |
Why?
|
| Optic Nerve Diseases | 1 | 2001 | 88 | 0.160 |
Why?
|
| Education | 1 | 2020 | 109 | 0.160 |
Why?
|
| Mitral Valve Stenosis | 1 | 2019 | 36 | 0.160 |
Why?
|
| Students, Medical | 1 | 2004 | 354 | 0.160 |
Why?
|
| Patient Care Team | 2 | 2017 | 542 | 0.160 |
Why?
|
| United Kingdom | 2 | 2020 | 190 | 0.160 |
Why?
|
| Safety-net Providers | 1 | 2019 | 51 | 0.160 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2019 | 12 | 0.160 |
Why?
|
| Patient Selection | 3 | 2011 | 694 | 0.160 |
Why?
|
| Fear | 1 | 2020 | 199 | 0.150 |
Why?
|
| Sex Characteristics | 1 | 2020 | 314 | 0.150 |
Why?
|
| Self-Management | 1 | 2020 | 95 | 0.150 |
Why?
|
| Health Personnel | 2 | 2020 | 506 | 0.150 |
Why?
|
| Biometry | 2 | 2017 | 136 | 0.150 |
Why?
|
| Dabigatran | 1 | 2018 | 26 | 0.150 |
Why?
|
| Perioperative Care | 1 | 2021 | 195 | 0.150 |
Why?
|
| Interviews as Topic | 2 | 2017 | 372 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2021 | 228 | 0.150 |
Why?
|
| Mesenteric Ischemia | 1 | 2018 | 30 | 0.150 |
Why?
|
| Sex Factors | 6 | 2015 | 1275 | 0.150 |
Why?
|
| Brain Death | 1 | 2019 | 61 | 0.150 |
Why?
|
| Endocarditis | 1 | 2019 | 105 | 0.150 |
Why?
|
| Death | 1 | 2019 | 72 | 0.150 |
Why?
|
| Rivaroxaban | 1 | 2018 | 55 | 0.150 |
Why?
|
| Office Visits | 2 | 2017 | 76 | 0.150 |
Why?
|
| Thiazoles | 1 | 2018 | 98 | 0.150 |
Why?
|
| Calcinosis | 1 | 2019 | 181 | 0.150 |
Why?
|
| Public Health | 3 | 2016 | 267 | 0.150 |
Why?
|
| Medically Uninsured | 2 | 2019 | 73 | 0.150 |
Why?
|
| Injections, Intravenous | 3 | 2014 | 248 | 0.150 |
Why?
|
| Policy Making | 1 | 2018 | 60 | 0.150 |
Why?
|
| Unemployment | 1 | 2018 | 20 | 0.150 |
Why?
|
| Heart Arrest | 1 | 2022 | 357 | 0.140 |
Why?
|
| Commerce | 1 | 2018 | 51 | 0.140 |
Why?
|
| Cost Savings | 2 | 2015 | 71 | 0.140 |
Why?
|
| Carrier Proteins | 1 | 2003 | 1035 | 0.140 |
Why?
|
| Skilled Nursing Facilities | 1 | 2017 | 5 | 0.140 |
Why?
|
| Pyridones | 1 | 2018 | 118 | 0.140 |
Why?
|
| Costs and Cost Analysis | 4 | 2015 | 163 | 0.140 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 196 | 0.140 |
Why?
|
| Self Medication | 1 | 2017 | 22 | 0.140 |
Why?
|
| Tissue Donors | 4 | 2019 | 483 | 0.140 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2019 | 164 | 0.140 |
Why?
|
| Anuria | 1 | 2017 | 13 | 0.140 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 277 | 0.140 |
Why?
|
| Parathyroid Hormone | 2 | 2011 | 73 | 0.140 |
Why?
|
| Family Health | 2 | 2019 | 256 | 0.140 |
Why?
|
| Program Development | 1 | 2018 | 182 | 0.140 |
Why?
|
| Acute Disease | 3 | 2021 | 1095 | 0.140 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2022 | 424 | 0.140 |
Why?
|
| Azathioprine | 1 | 2017 | 54 | 0.140 |
Why?
|
| Veterans Health | 1 | 2018 | 175 | 0.140 |
Why?
|
| Pravastatin | 2 | 2007 | 22 | 0.130 |
Why?
|
| Treatment Failure | 2 | 2012 | 335 | 0.130 |
Why?
|
| HIV | 1 | 2018 | 181 | 0.130 |
Why?
|
| Emergency Medical Services | 1 | 2001 | 398 | 0.130 |
Why?
|
| Ischemic Attack, Transient | 1 | 2016 | 56 | 0.130 |
Why?
|
| Metals | 1 | 2017 | 63 | 0.130 |
Why?
|
| Insurance Coverage | 1 | 2017 | 120 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 207 | 0.130 |
Why?
|
| Health Care Rationing | 2 | 2021 | 58 | 0.130 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2018 | 102 | 0.130 |
Why?
|
| Cholesterol, HDL | 1 | 2018 | 355 | 0.130 |
Why?
|
| Aortic Valve | 1 | 2019 | 444 | 0.130 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 439 | 0.130 |
Why?
|
| Societies, Medical | 3 | 2020 | 700 | 0.130 |
Why?
|
| Financing, Government | 1 | 2016 | 30 | 0.130 |
Why?
|
| Glycemic Index | 1 | 2015 | 19 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2018 | 306 | 0.130 |
Why?
|
| Computer Simulation | 3 | 2017 | 650 | 0.130 |
Why?
|
| Drinking | 1 | 2015 | 34 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 2 | 2014 | 161 | 0.120 |
Why?
|
| Physician-Patient Relations | 2 | 2017 | 427 | 0.120 |
Why?
|
| Poisson Distribution | 2 | 2015 | 51 | 0.120 |
Why?
|
| Inappropriate Prescribing | 1 | 2015 | 35 | 0.120 |
Why?
|
| Membrane Proteins | 1 | 2003 | 1538 | 0.120 |
Why?
|
| BK Virus | 1 | 2016 | 60 | 0.120 |
Why?
|
| Drug Therapy, Combination | 4 | 2016 | 1158 | 0.120 |
Why?
|
| Rare Diseases | 1 | 2017 | 191 | 0.120 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 338 | 0.120 |
Why?
|
| Parents | 2 | 2022 | 1024 | 0.120 |
Why?
|
| Alleles | 3 | 2005 | 1615 | 0.120 |
Why?
|
| Polyomavirus Infections | 1 | 2016 | 90 | 0.120 |
Why?
|
| Menopause | 1 | 2015 | 74 | 0.120 |
Why?
|
| Tumor Virus Infections | 1 | 2016 | 134 | 0.120 |
Why?
|
| Communicable Diseases | 1 | 2017 | 160 | 0.120 |
Why?
|
| Hematologic Diseases | 1 | 2016 | 79 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 1 | 2015 | 127 | 0.120 |
Why?
|
| International Cooperation | 2 | 2017 | 157 | 0.120 |
Why?
|
| Immune Tolerance | 1 | 2015 | 144 | 0.120 |
Why?
|
| Half-Life | 1 | 2015 | 156 | 0.120 |
Why?
|
| Canada | 4 | 2019 | 286 | 0.120 |
Why?
|
| Coronary Restenosis | 1 | 2014 | 24 | 0.120 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 412 | 0.110 |
Why?
|
| Obesity, Abdominal | 1 | 2014 | 37 | 0.110 |
Why?
|
| Contraindications | 1 | 2014 | 78 | 0.110 |
Why?
|
| Insurance Claim Review | 2 | 2014 | 27 | 0.110 |
Why?
|
| Hemoglobin A | 1 | 2014 | 22 | 0.110 |
Why?
|
| Endovascular Procedures | 1 | 2022 | 726 | 0.110 |
Why?
|
| Digoxin | 1 | 2014 | 43 | 0.110 |
Why?
|
| Tissue Banks | 1 | 2014 | 27 | 0.110 |
Why?
|
| Linear Models | 4 | 2015 | 681 | 0.110 |
Why?
|
| Catheter Ablation | 1 | 2016 | 233 | 0.110 |
Why?
|
| Hemoglobinometry | 1 | 2013 | 4 | 0.110 |
Why?
|
| Drug Approval | 2 | 2012 | 43 | 0.110 |
Why?
|
| Capitation Fee | 1 | 2013 | 3 | 0.110 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2013 | 15 | 0.110 |
Why?
|
| Cardiology | 1 | 2019 | 507 | 0.110 |
Why?
|
| Haplotypes | 1 | 2015 | 520 | 0.110 |
Why?
|
| Ownership | 3 | 2019 | 33 | 0.110 |
Why?
|
| Urological Agents | 1 | 2013 | 5 | 0.110 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2013 | 31 | 0.110 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2013 | 18 | 0.110 |
Why?
|
| United Nations | 1 | 2013 | 12 | 0.100 |
Why?
|
| Transplantation | 1 | 2013 | 27 | 0.100 |
Why?
|
| Adiposity | 1 | 2014 | 190 | 0.100 |
Why?
|
| Allografts | 2 | 2024 | 176 | 0.100 |
Why?
|
| Prosthesis-Related Infections | 2 | 2015 | 173 | 0.100 |
Why?
|
| Heart Diseases | 2 | 2015 | 495 | 0.100 |
Why?
|
| Catheterization | 1 | 2014 | 225 | 0.100 |
Why?
|
| Observation | 1 | 2012 | 42 | 0.100 |
Why?
|
| Health Care Reform | 3 | 2020 | 51 | 0.100 |
Why?
|
| Gene Frequency | 2 | 2004 | 728 | 0.100 |
Why?
|
| Motivation | 1 | 2014 | 318 | 0.100 |
Why?
|
| Influenza, Human | 1 | 2019 | 662 | 0.100 |
Why?
|
| Internal Medicine | 2 | 2011 | 147 | 0.100 |
Why?
|
| Radiography | 1 | 2014 | 802 | 0.100 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 552 | 0.100 |
Why?
|
| Orphan Drug Production | 1 | 2012 | 5 | 0.100 |
Why?
|
| Forecasting | 1 | 2013 | 352 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2020 | 913 | 0.100 |
Why?
|
| Long-Term Care | 1 | 2012 | 65 | 0.100 |
Why?
|
| Graft vs Host Disease | 1 | 2016 | 503 | 0.100 |
Why?
|
| Endothelial Cells | 2 | 2013 | 505 | 0.090 |
Why?
|
| Bone Density | 1 | 2014 | 318 | 0.090 |
Why?
|
| Postoperative Period | 4 | 2022 | 333 | 0.090 |
Why?
|
| California | 1 | 2012 | 130 | 0.090 |
Why?
|
| Kidney Glomerulus | 2 | 2024 | 77 | 0.090 |
Why?
|
| Recurrence | 3 | 2016 | 1390 | 0.090 |
Why?
|
| Reoperation | 2 | 2024 | 828 | 0.090 |
Why?
|
| Government Agencies | 1 | 2011 | 11 | 0.090 |
Why?
|
| Netherlands | 2 | 2011 | 38 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 2878 | 0.090 |
Why?
|
| Aging | 2 | 2010 | 1181 | 0.090 |
Why?
|
| Geriatric Assessment | 1 | 2012 | 175 | 0.090 |
Why?
|
| Life Style | 1 | 2014 | 415 | 0.090 |
Why?
|
| Sulfonylurea Compounds | 1 | 2010 | 17 | 0.090 |
Why?
|
| Spironolactone | 1 | 2010 | 21 | 0.090 |
Why?
|
| Mutation | 1 | 2004 | 5906 | 0.090 |
Why?
|
| Stem Cells | 2 | 2013 | 710 | 0.080 |
Why?
|
| Child | 12 | 2022 | 24609 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2017 | 996 | 0.080 |
Why?
|
| Palliative Care | 1 | 2014 | 432 | 0.080 |
Why?
|
| Primary Prevention | 1 | 2011 | 172 | 0.080 |
Why?
|
| Renal Elimination | 2 | 2019 | 10 | 0.080 |
Why?
|
| Electrocardiography | 2 | 2023 | 976 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2013 | 472 | 0.080 |
Why?
|
| Psychotropic Drugs | 1 | 2010 | 125 | 0.080 |
Why?
|
| Analgesics | 1 | 2010 | 127 | 0.080 |
Why?
|
| Geography | 1 | 2009 | 116 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 2055 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2011 | 363 | 0.080 |
Why?
|
| Anxiety | 2 | 2022 | 944 | 0.080 |
Why?
|
| Internationality | 2 | 2020 | 133 | 0.070 |
Why?
|
| Lung | 1 | 2016 | 1492 | 0.070 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 164 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 3 | 2014 | 231 | 0.070 |
Why?
|
| Receptors, Angiotensin | 1 | 2007 | 21 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2016 | 1097 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2011 | 390 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 288 | 0.070 |
Why?
|
| Stakeholder Participation | 2 | 2018 | 25 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2009 | 353 | 0.070 |
Why?
|
| Calcium Phosphates | 1 | 2007 | 9 | 0.070 |
Why?
|
| Lovastatin | 1 | 2007 | 22 | 0.070 |
Why?
|
| Prolactin | 1 | 2007 | 113 | 0.070 |
Why?
|
| Heparin Antagonists | 1 | 2007 | 5 | 0.070 |
Why?
|
| Bacteremia | 1 | 2011 | 400 | 0.070 |
Why?
|
| Patient Admission | 1 | 2008 | 185 | 0.070 |
Why?
|
| Simvastatin | 1 | 2007 | 75 | 0.070 |
Why?
|
| Heptanoic Acids | 1 | 2007 | 79 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 263 | 0.070 |
Why?
|
| Hypnotics and Sedatives | 1 | 2007 | 133 | 0.060 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2006 | 93 | 0.060 |
Why?
|
| Isosorbide Dinitrate | 1 | 2005 | 4 | 0.060 |
Why?
|
| Hydralazine | 1 | 2005 | 8 | 0.060 |
Why?
|
| Interdisciplinary Communication | 2 | 2017 | 129 | 0.060 |
Why?
|
| Alberta | 2 | 2016 | 45 | 0.060 |
Why?
|
| Indians, North American | 2 | 2018 | 58 | 0.060 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2005 | 10 | 0.060 |
Why?
|
| Body Height | 1 | 2007 | 216 | 0.060 |
Why?
|
| Equipment Failure | 1 | 2006 | 121 | 0.060 |
Why?
|
| Insulin | 1 | 2010 | 1203 | 0.060 |
Why?
|
| Hemarthrosis | 1 | 2005 | 2 | 0.060 |
Why?
|
| Diet Surveys | 1 | 2005 | 98 | 0.060 |
Why?
|
| Pyrroles | 1 | 2007 | 184 | 0.060 |
Why?
|
| Pregnancy | 2 | 2015 | 7221 | 0.060 |
Why?
|
| Biopsy | 2 | 2019 | 1242 | 0.060 |
Why?
|
| Demography | 1 | 2006 | 239 | 0.060 |
Why?
|
| Hemophilia A | 1 | 2005 | 21 | 0.060 |
Why?
|
| Erythrocyte Count | 1 | 2004 | 21 | 0.060 |
Why?
|
| Blood Coagulation Factors | 1 | 2005 | 35 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 604 | 0.060 |
Why?
|
| Prednisolone | 2 | 2004 | 74 | 0.060 |
Why?
|
| Child, Preschool | 7 | 2017 | 14151 | 0.060 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 225 | 0.060 |
Why?
|
| Polyethylenes | 1 | 2004 | 8 | 0.060 |
Why?
|
| Epoxy Compounds | 1 | 2004 | 18 | 0.060 |
Why?
|
| Nursing Homes | 1 | 2005 | 85 | 0.060 |
Why?
|
| Complement Inactivating Agents | 1 | 2024 | 12 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 2371 | 0.060 |
Why?
|
| Europe | 2 | 2021 | 359 | 0.060 |
Why?
|
| Inflammation | 2 | 2018 | 1447 | 0.060 |
Why?
|
| Arm | 1 | 2024 | 81 | 0.060 |
Why?
|
| Complement System Proteins | 1 | 2024 | 58 | 0.060 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2005 | 109 | 0.060 |
Why?
|
| Orthopedic Procedures | 1 | 2004 | 69 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2005 | 605 | 0.050 |
Why?
|
| Anticholesteremic Agents | 1 | 2006 | 235 | 0.050 |
Why?
|
| Prolyl Hydroxylases | 1 | 2023 | 3 | 0.050 |
Why?
|
| Calcium Channel Agonists | 1 | 2003 | 11 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2023 | 22 | 0.050 |
Why?
|
| Fasting | 1 | 2004 | 293 | 0.050 |
Why?
|
| Long QT Syndrome | 1 | 2024 | 83 | 0.050 |
Why?
|
| Cholesterol | 1 | 2006 | 540 | 0.050 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 489 | 0.050 |
Why?
|
| Calcitriol | 1 | 2003 | 80 | 0.050 |
Why?
|
| Fluvoxamine | 1 | 2022 | 25 | 0.050 |
Why?
|
| Direct Service Costs | 1 | 2002 | 8 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2005 | 291 | 0.050 |
Why?
|
| Value of Life | 1 | 2002 | 9 | 0.050 |
Why?
|
| Transferrins | 1 | 2022 | 2 | 0.050 |
Why?
|
| Paroxetine | 1 | 2022 | 28 | 0.050 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2002 | 21 | 0.050 |
Why?
|
| Fluoxetine | 1 | 2022 | 43 | 0.050 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2022 | 5 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 564 | 0.050 |
Why?
|
| Social Values | 1 | 2002 | 47 | 0.050 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2002 | 32 | 0.050 |
Why?
|
| Bradycardia | 1 | 2022 | 60 | 0.050 |
Why?
|
| Hepcidins | 1 | 2022 | 26 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 69 | 0.050 |
Why?
|
| Ischemia | 2 | 2006 | 353 | 0.050 |
Why?
|
| Levofloxacin | 1 | 2022 | 46 | 0.050 |
Why?
|
| Vaginal Smears | 1 | 2002 | 48 | 0.050 |
Why?
|
| Homozygote | 1 | 2004 | 547 | 0.050 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2022 | 19 | 0.050 |
Why?
|
| Prescriptions | 1 | 2022 | 39 | 0.050 |
Why?
|
| Ultrafiltration | 1 | 2021 | 14 | 0.050 |
Why?
|
| Organ Transplantation | 1 | 2004 | 168 | 0.050 |
Why?
|
| Heterozygote | 1 | 2004 | 672 | 0.050 |
Why?
|
| Bias | 1 | 2002 | 132 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2006 | 538 | 0.050 |
Why?
|
| Mammography | 1 | 2002 | 114 | 0.050 |
Why?
|
| Retreatment | 1 | 2001 | 89 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 3175 | 0.050 |
Why?
|
| Likelihood Functions | 1 | 2001 | 114 | 0.050 |
Why?
|
| Amoxicillin | 1 | 2022 | 121 | 0.050 |
Why?
|
| Ireland | 1 | 2021 | 28 | 0.050 |
Why?
|
| Smoking | 1 | 2007 | 1049 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2002 | 255 | 0.050 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2000 | 26 | 0.040 |
Why?
|
| Pyridoxine | 1 | 2000 | 14 | 0.040 |
Why?
|
| International Agencies | 1 | 2020 | 30 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 297 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 1026 | 0.040 |
Why?
|
| Social Class | 1 | 2001 | 190 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1592 | 0.040 |
Why?
|
| Data Collection | 1 | 2022 | 378 | 0.040 |
Why?
|
| Health Facilities, Proprietary | 1 | 2019 | 3 | 0.040 |
Why?
|
| Diabetic Retinopathy | 1 | 2002 | 156 | 0.040 |
Why?
|
| Optic Nerve | 1 | 2001 | 114 | 0.040 |
Why?
|
| Health Literacy | 1 | 2020 | 75 | 0.040 |
Why?
|
| Base Sequence | 1 | 2004 | 3109 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2022 | 295 | 0.040 |
Why?
|
| Review Literature as Topic | 1 | 2019 | 44 | 0.040 |
Why?
|
| Gene Expression | 1 | 2004 | 1554 | 0.040 |
Why?
|
| Survival | 1 | 2019 | 19 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 89 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2021 | 220 | 0.040 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2019 | 21 | 0.040 |
Why?
|
| Health Promotion | 1 | 2002 | 386 | 0.040 |
Why?
|
| Paraproteinemias | 1 | 2019 | 16 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2020 | 220 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 3898 | 0.040 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2019 | 21 | 0.040 |
Why?
|
| Aorta | 1 | 2022 | 545 | 0.040 |
Why?
|
| Growth | 1 | 2019 | 106 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2001 | 292 | 0.040 |
Why?
|
| Cadaver | 2 | 2011 | 130 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2005 | 827 | 0.040 |
Why?
|
| Podocytes | 1 | 2019 | 73 | 0.040 |
Why?
|
| Health Facilities | 1 | 2018 | 61 | 0.040 |
Why?
|
| Urea | 1 | 2019 | 231 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2019 | 402 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2019 | 179 | 0.040 |
Why?
|
| Contraindications, Drug | 1 | 2017 | 3 | 0.040 |
Why?
|
| Erythrocyte Transfusion | 1 | 2019 | 129 | 0.040 |
Why?
|
| Mitral Valve | 1 | 2019 | 252 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2018 | 283 | 0.030 |
Why?
|
| Glucose | 1 | 2022 | 876 | 0.030 |
Why?
|
| Seasons | 1 | 2019 | 312 | 0.030 |
Why?
|
| Hospitals | 1 | 2019 | 391 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 95 | 0.030 |
Why?
|
| Reference Values | 1 | 2018 | 719 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2019 | 496 | 0.030 |
Why?
|
| Lipids | 1 | 2020 | 519 | 0.030 |
Why?
|
| Parent-Child Relations | 1 | 2018 | 248 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2015 | 47 | 0.030 |
Why?
|
| Blood Vessel Prosthesis | 2 | 2015 | 520 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 780 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 253 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 133 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2016 | 132 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2016 | 198 | 0.030 |
Why?
|
| Hydroxychloroquine | 1 | 2015 | 17 | 0.030 |
Why?
|
| Culture | 1 | 2015 | 68 | 0.030 |
Why?
|
| Cost Control | 1 | 2015 | 24 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 219 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 321 | 0.030 |
Why?
|
| Health Priorities | 1 | 2015 | 37 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 880 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2014 | 89 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 528 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 508 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 668 | 0.030 |
Why?
|
| Progestins | 1 | 2014 | 48 | 0.030 |
Why?
|
| Inventions | 1 | 2013 | 17 | 0.030 |
Why?
|
| Antirheumatic Agents | 1 | 2015 | 120 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2018 | 818 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2012 | 28 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 252 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2014 | 224 | 0.030 |
Why?
|
| Reticulocytes | 1 | 2012 | 43 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2015 | 384 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2012 | 88 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1893 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 3571 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 171 | 0.020 |
Why?
|
| Infant | 3 | 2016 | 12609 | 0.020 |
Why?
|
| Lidocaine | 1 | 2012 | 47 | 0.020 |
Why?
|
| Neuralgia | 1 | 2012 | 43 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2018 | 859 | 0.020 |
Why?
|
| Equipment Design | 1 | 2013 | 590 | 0.020 |
Why?
|
| Benzhydryl Compounds | 1 | 2012 | 66 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2014 | 200 | 0.020 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2011 | 20 | 0.020 |
Why?
|
| Estrogens | 1 | 2014 | 503 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 65 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 183 | 0.020 |
Why?
|
| Organization and Administration | 1 | 2010 | 4 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2016 | 8275 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2009 | 33 | 0.020 |
Why?
|
| Age of Onset | 1 | 2011 | 600 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2009 | 105 | 0.020 |
Why?
|
| Software | 1 | 2014 | 687 | 0.020 |
Why?
|
| Pediatrics | 1 | 2018 | 1158 | 0.020 |
Why?
|
| Educational Status | 1 | 2008 | 274 | 0.020 |
Why?
|
| Decision Trees | 1 | 2007 | 50 | 0.020 |
Why?
|
| Logical Observation Identifiers Names and Codes | 1 | 2006 | 1 | 0.020 |
Why?
|
| Hospital Records | 1 | 2006 | 8 | 0.020 |
Why?
|
| Forms and Records Control | 1 | 2006 | 11 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2006 | 108 | 0.020 |
Why?
|
| Antilymphocyte Serum | 1 | 2006 | 55 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 118 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 2006 | 121 | 0.020 |
Why?
|
| Phosphatidylglycerols | 1 | 2005 | 6 | 0.020 |
Why?
|
| Deoxycholic Acid | 1 | 2005 | 13 | 0.020 |
Why?
|
| Factor VII | 1 | 2005 | 16 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2005 | 37 | 0.020 |
Why?
|
| Medical Records | 1 | 2006 | 191 | 0.020 |
Why?
|
| Probability | 1 | 2006 | 318 | 0.020 |
Why?
|
| Factor VIIa | 1 | 2005 | 24 | 0.010 |
Why?
|
| Fluconazole | 1 | 2005 | 48 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2006 | 199 | 0.010 |
Why?
|
| Models, Economic | 1 | 2005 | 51 | 0.010 |
Why?
|
| Amphotericin B | 1 | 2005 | 90 | 0.010 |
Why?
|
| Factor VIII | 1 | 2005 | 45 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2006 | 275 | 0.010 |
Why?
|
| Home Care Services | 1 | 2005 | 74 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2005 | 262 | 0.010 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 22 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2006 | 430 | 0.010 |
Why?
|
| Uric Acid | 1 | 2004 | 95 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2006 | 298 | 0.010 |
Why?
|
| Triglycerides | 1 | 2006 | 571 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2005 | 433 | 0.010 |
Why?
|
| Critical Care | 1 | 2007 | 656 | 0.010 |
Why?
|
| Animals | 1 | 2000 | 34304 | 0.010 |
Why?
|